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Background
In this cross-sectional survey our purpose is to evaluate
the clinical outcome and safety of allergoid sublingual
immunotherapy in cat-allergic patients suffering from
rhinoconjunctivitis and / or asthma.
Methods
All patients were drawn anonymously from twenty-one
practices across Germany. For this survey, a question-
naire was designed to standardize the patient interviews
that were performed by the investigators. Patients were
prescribed monomeric allergoid sublingual tablets for an
initial up-dosing therapy and afterwards for maintenance
therapy. Primary endpoints were improvement of symp-
toms, medications score and safety during therapy with
monomeric allergoids.
Results
In total, 70 patients completed the questionnaire. Of 70
patients, 35.7% were males and 64.3% females. Regard-
ing rhinitis symptoms, almost thirty percent (29.1%) of
the patients had become symptom-free during the first
year of therapy. This number increased to 52.8% of the
remaining patients in the second year, and to 80% of
the remaining patients in the third year of therapy. Simi-
lar results were valid for conjunctivitis with 35.6%,
55.2% and 72.7% from the first to the third year of ther-
apy. For asthmatic patients, 35.1% had become symp-
tom-free during the first year, 58.3% during the second
year, and 70% during the third year of therapy. At base-
line, usage of asthmatic medication was 1.33 ± 1.48
(mean ± SD) relative to 0.68 ± 1.23 (mean ± SD) at the
time of the questionnaire conduct, with p ≤ 0.05. For
anti-allergic medication, baseline medication score was
1.01 ± 1.37 (mean ± SD) relative to 0.45 ± 0.87 (mean ±
SD), with p ≤ 0.001. Regarding safety, no events of
death, no anaphylactic reactions, no serious adverse
events, and no systemic adverse reactions occurred.
Only seven local adverse reactions were reported in
7 patients. Besides the major endpoints, secondary end-
points such as patients’ improvement of quality of life,
patients’ compliance, patients’ satisfaction, and trust in
the therapy were remarkably enhanced.
Conclusions
Monomeric allergoid sublingual tablets show clinical
advantages in a practice environment and under real-life
setting conditions. The results of other studies could be
reinforced by the results of our study, with significant
reduction in medication score, symptom improvement,
and a considerable safety outcome. It can be claimed
that a sublingual monomeric tablet therapy is safe and
well tolerated and significantly reduces rhinitis symp-
toms in cat-allergic patients.
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